CareFusion statement regarding company-funded clinical study
In response to a recent media story regarding the validity of a CareFusion-funded clinical study, CareFusion issued the following statement:
Jan 5, 2014
Our products are safe and effective. In particular, our skin prep product, ChloraPrep, has been proven effective when used in conjunction with best clinical practices to effectively kill microorganisms prior to surgery or injection. The active agents in ChloraPrep, chlorhexidine gluconate (CHG) in combination with isopropyl alcohol, have been acknowledged for years by multiple independent clinical organizations, including the Centers for Disease Control and Prevention, as a superior agent in prepping skin prior to an invasive procedure. There is a large body of evidence supporting these recommendations that has been published, peer reviewed and recognized by some of the best scientific minds in the world.
A recent news report included the unsubstantiated allegations of a former employee about a CareFusion-funded clinical study published in the New England Journal of Medicine. The government investigated the matter and did not take action on the former employee’s allegations related to the study or its validity. The settlement agreement announced by the government and CareFusion on January 9 did not pertain to the clinical study or its analysis.
As it relates to allegations about CareFusion’s past marketing practices or projects with a health care professional that ended years ago, we chose to settle and resolve the matter to avoid the ongoing cost and distraction. Since the formation of CareFusion in 2009, we have continuously updated and invested in our compliance program to help ensure that today we are adhering to best practices in our industry and the high standards we've set for ourselves.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
For more information on BD, please visit bd.com.
Back to News Releases